LabVantage Solutions Unveils LIMS 8.9: Transforming Lab Productivity and Efficiency LabVantage Solutions, Inc., a global leader in laboratory informatics, has announced the launch of LabVantage 8.9, the latest evolution of its cutting-edge Laboratory Information Management System (LIMS). This new release…
Protagonist and Takeda Announce Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ: PTGX) and Takeda (TSE: 4502/NYSE: TAK) have announced positive topline results from the Phase 3 VERIFY study, evaluating rusfertide in…
QIAGEN Takes Legal Action to Defend QuantiFERON Intellectual Property and Protect Innovations in Latent Tuberculosis Testing QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a patent infringement complaint against bioMérieux S.A. (EPA: BIM), reinforcing its commitment to protecting…
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases Seismic Therapeutic, Inc., a pioneering machine learning immunology company, has announced the presentation of preclinical data for its novel immunoglobulin E (IgE) protease, S-8484. The data reveal S-8484’s ability to…
Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a leading biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases, has officially launched the Phase 3 ALPHA-ORBIT clinical trial of…
Immune-Onc Therapeutics Doses First Patient with IO-108 in Global Phase 1b/2 Liver Cancer Study in Collaboration with Roche Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage biopharmaceutical company focused on developing innovative therapies in immunology and oncology, has announced a significant…
Healx Begins Phase 2 Trial Dosing for HLX-1502 in Neurofibromatosis Type 1 Healx, an AI-driven, clinical-stage biotechnology company focused on developing treatments for rare diseases, has announced a major milestone in its efforts to provide new therapeutic options for patients…
Halda Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of HLD-0915 for Metastatic Castration-Resistant Prostate Cancer Halda Therapeutics, a clinical-stage biotechnology company focused on developing a novel class of cancer therapies known as RIPTAC™ (Regulated Induced Proximity Targeting Chimeras)…
AN2 Therapeutics Announces Strategic Update on Phase 3 EBO-301 Trial for Treatment-Refractory MAC Lung Disease AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing innovative small-molecule therapeutics leveraging its proprietary boron chemistry platform, has announced a…
Seaport Therapeutics Investigates Clinical Trial Design and Placebo Response in Major Depressive Disorder Studies Seaport Therapeutics (“Seaport” or “the Company”), a clinical-stage biopharmaceutical company focused on advancing innovative neuropsychiatric medicines, has presented a new meta-analysis examining the impact of clinical…
ReCerise and NCCS Forge Strategic Research Collaboration to Advance Hepatocellular Carcinoma Treatment ReCerise Therapeutics Inc. (“ReCerise”), a pioneering biotechnology company dedicated to the research and development of first-in-class oncology therapeutics, has officially announced a groundbreaking research collaboration with the National…
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company leveraging its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs, has announced promising initial results from the ELIMINATE-B clinical trial. This trial…